TRDA
Income statement / Annual
Last year (2025), Entrada Therapeutics Inc's total revenue was $25.42 M,
a decrease of 87.94% from the previous year.
In 2025, Entrada Therapeutics Inc's net income was -$143.75 M.
See Entrada Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$25.42 M |
$210.78 M |
$129.01 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$4.10 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$326.00 K
|
$104.00 K
|
| Gross Profit |
$21.33 M
|
$210.78 M
|
$129.01 M
|
$0.00
|
$0.00
|
-$326.00 K
|
-$104.00 K
|
| Gross Profit Ratio |
0.84
|
1
|
1
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$142.27 M
|
$125.31 M
|
$99.88 M
|
$66.61 M
|
$35.93 M
|
$21.10 M
|
$8.22 M
|
| General & Administrative Expenses |
$41.05 M
|
$38.47 M
|
$32.29 M
|
$30.64 M
|
$15.20 M
|
$0.00
|
$3.61 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$41.05 M
|
$38.47 M
|
$32.29 M
|
$30.64 M
|
$15.20 M
|
$5.24 M
|
$3.61 M
|
| Other Expenses |
-$6.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$177.32 M
|
$163.77 M
|
$132.18 M
|
$97.25 M
|
$51.13 M
|
$26.34 M
|
$11.82 M
|
| Cost And Expenses |
$181.42 M
|
$163.77 M
|
$132.18 M
|
$97.25 M
|
$51.13 M
|
$26.67 M
|
$11.82 M
|
| Interest Income |
$0.00
|
$19.47 M
|
$15.22 M
|
$2.63 M
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$2.63 M
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$425.00 K
|
$3.77 M
|
$2.84 M
|
$1.90 M
|
$1.12 M
|
$326.00 K
|
$104.00 K
|
| EBITDA |
-$142.40 M |
$50.78 M |
-$321.00 K |
-$95.35 M |
-$50.01 M |
-$26.20 M |
-$11.72 M |
| EBITDA Ratio |
-5.6
|
0.24
|
-0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-6.14
|
0.22
|
-0.02
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$13.17 M
|
$19.47 M
|
$15.22 M
|
$2.63 M
|
-$31.00 K
|
$144.00 K
|
$6.72 M
|
| Income Before Tax |
-$142.83 M
|
$66.49 M
|
$12.06 M
|
-$94.62 M
|
-$51.16 M
|
-$26.52 M
|
-$5.10 M
|
| Income Before Tax Ratio |
-5.62
|
0.32
|
0.09
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$924.00 K
|
$859.00 K
|
$18.74 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$143.75 M
|
$65.63 M
|
-$6.69 M
|
-$94.62 M
|
-$51.16 M
|
-$26.52 M
|
-$4.65 M
|
| Net Income Ratio |
-5.65
|
0.31
|
-0.05
|
0
|
0
|
0
|
0
|
| EPS |
-3.47 |
1.76 |
-0.2 |
-2.79 |
-1.6 |
-0.84 |
-4.44 |
| EPS Diluted |
-3.47 |
1.68 |
-0.2 |
-2.79 |
-1.6 |
-0.84 |
-4.44 |
| Weighted Average Shares Out |
$41.37 M
|
$37.31 M
|
$33.05 M
|
$31.29 M
|
$31.22 M
|
$31.25 M
|
$1.05 M
|
| Weighted Average Shares Out Diluted |
$41.37 M
|
$39.00 M
|
$33.05 M
|
$31.29 M
|
$31.22 M
|
$31.25 M
|
$1.05 M
|
| Link |
|
|
|
|
|
|
|
